Journal
TRENDS IN CARDIOVASCULAR MEDICINE
Volume 10, Issue 4, Pages 143-148Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/S1050-1738(00)00044-X
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL-52233, HL-34836] Funding Source: Medline
- NINDS NIH HHS [NS-10828] Funding Source: Medline
Ask authors/readers for more resources
The 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, or statins, are potent inhibitors of cholesterol synthesis and large clinical trials have demonstrated that these agents reduce cholesterol and the incidence of cardiovascular diseases. Recent evidence, however, suggests that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels. Because statins also inhibit the synthesis of isoprenoid intermediates in the cholesterol biosynthetic pathway, they may have pleiotropic effects on vascular wall cells. In particular, the small GTP-binding protein, Rho, whose membrane localization and activity are affected by post-translational isoprenylation, may play an important role in mediating the direct vascular effects of statins. (Trends Cardiovasc Med 2000;10:143-148). (C) 2001 Elsevier Science Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available